查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553581

照护现场传染病检查市场规模、份额和趋势分析报告：2024-2030 年按技术、疾病、最终用途、地区和细分市场进行的预测

Point Of Care Infectious Disease Testing Market Size, Share & Trends Analysis Report By Technology, By Disease (HIV POC, Clostridium Difficile POC), By End-use, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

照护现场传染病检查市场的成长与趋势：

Grand View Research, Inc.最新报告显示，到2030年，全球照护现场传染病检查市场规模预计将达到157.6亿美元，复合年增长率为4.3%。

以患者为中心的服务的新兴趋势，加上复杂感染疾病病率的上升，预计将急剧增加对可携式和准确检测设备的需求，推动市场成长。这些设备能够快速检测感染疾病的潜力正在推动估计市场的发展。

此外，这些设备带来的患者照护创新正在推动对分散式检查环境不断增长的需求。预计到 2025 年，新产品研发和市场开拓的投资增加将刺激照护现场感染疾病诊断市场的发展。

例如，欧盟计划研究小组开发的一种新的「光碟实验室」技术可以帮助诊断包括疟疾在内的各种感染疾病。即时治疗的引入可以实现更快的诊断。这可以实现精确的药物剂量并影响吸收。

照护现场传染病检查市场报告亮点

  • COVID-19 细分市场占据主导地位，到 2023 年将占据 67% 的份额。这一高比率是由于感染疾病患者数量不断增加以及对快速且易于使用的诊断测试解决方案的需求。
  • 预计侧流免疫测量在预测期内的复合年增长率将达到 5.7%，是最快的。这一增长是由呼吸系统疾病等感染疾病的日益流行以及照护现场诊断设备的技术进步所推动的。
  • 预计家庭产业在预测期内将以 5.5% 的复合年增长率成长最快。这是由于老年人越来越多地采用 POC 测试，并且越来越重视个人化、预防性居家照护设施。
  • 由于在政府的充分支持下，感染疾病发病率和盛行率不断上升，预计亚太地区将在预测期内出现最快的增长。

目录

第一章调查方法和范围

第 2 章执行摘要

第 3 章照护现场传染病检查市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 照护现场传染病检查市场分析工具
    • 波特的分析
    • PESTEL分析

第四章照护现场传染病检查市场：技术估算与趋势分析

  • 细分仪表板
  • 照护现场传染病检查市场：2023 年和 2030 年技术变化分析
  • 侧流免疫检测
  • 凝集试验
  • 流通测试/免疫富集测定
  • 分子诊断
  • 其他的

第五章照护现场传染病检查市场：依疾病分类的估计与趋势分析

  • 细分仪表板
  • 照护现场传染病检查市场：2023 年及 2030 年依疾病分类的变异分析
  • HIV POC
  • 困难梭状芽孢桿菌POC
  • HBV POC
  • 肺炎或链球菌相关感染疾病
  • 呼吸道融合细胞病毒(RSV) POC
  • HPV POC
  • 流感/流感 POC
  • HCV POC
  • MRSA POC
  • 结核病和抗药性结核病的 POC
  • HSV POC
  • COVID-19
  • 其他感染疾病

第六章照护现场传染病检查市场：依最终用途分类的估计与趋势分析

  • 细分仪表板
  • 照护现场传染病检查市场：2023 年和 2030 年最终用途的变化分析
  • 诊所
  • 医院
  • 房子
  • 生活协助医疗设施
  • 实验室

第七章照护现场传染病检查市场：区域估计与趋势分析

  • 2023 年和 2030 年按地区照护现场传染病检查市场占有率
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Abbott
    • Thermo Fisher Scientific Inc
    • F. Hoffmann-La Roche Ltd
    • Siemens Healthineers
    • Becton, Dickinson &Company
    • Chembio Diagnostics Inc.
    • Trinity Biotech
    • Cardinal Health
    • Quest Diagnostics Incorporated
    • Bio-Rad Laboratories Inc.
    • bioMerieux SA
    • Sight Diagnostics Ltd.
    • Gene POC
    • Trivitron Healthcare
    • OJ-Bio Ltd.
    • Ortho-Clinical Diagnostics.
简介目录
Product Code: GVR-1-68038-569-4

Point Of Care Infectious Disease Testing Market Growth & Trends:

The global point of care infectious disease testing market size is expected to reach USD 15.76 billion by 2030, registering a CAGR of 4.3%, according to a new report by Grand View Research, Inc. The emerging trend of patient-centric services coupled with escalating incidence rates of complicated infectious disorders is expected to upsurge the demand for portable and accurate detection devices, thus resulting in market growth. The potential in these devices to enable rapid detection of infectious diseases is attributive for the estimated market.

Moreover, revolutionizing patient care brought about by these devices is responsible for the rising demand for decentralized testing settings. Rise in the investments for R&D and development of new products is expected to spur progress in point-of-care infectious disease diagnostics market through to 2025.

For instance, development of a new 'lab-on-a-disc' technology developed by an EU project research team aids in the diagnosis of different infectious diseases including malaria. It enables faster diagnosis as a consequence of implementation of point-of-care treatment. This allows precise drugs administration thus influencing adoption rate.

Point Of Care Infectious Disease Testing Market Report Highlights:

  • COVID-19 segment dominated the market and accounted for a share of 67% in 2023. This high percentage can be attributed to the rising number of infectious cases and need for fast and accessible diagnostics testing solutions.
  • Lateral flow immunoassay is expected to register the fastest CAGR of 5.7% during the forecast period. The growth can be attributed to increasing prevalence of infectious diseases such as respiratory disease and technological advancements in point of care diagnostics device.
  • The home segment is projected to grow at the fastest CAGR of 5.5% over the forecast period, owing to increasing adoption of point of care testing among geriatric population and increasing emphasis on personalized and preventive home care facilities.
  • Asia Pacific region is expected to showcase the fastest growth over the forecast period due to rising incidence and prevalence rates of infectious diseases with suitable government support

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Point of Care Infectious Disease Testing Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Billion)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Point of Care Infectious Disease Testing Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Point of Care Infectious Disease Testing Market: Technology Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Point of Care Infectious Disease Testing Market: Technology Movement Analysis, 2023 & 2030 (USD Billion)
  • 4.3. Lateral Flow Immunoassay
    • 4.3.1. Lateral Flow Immunoassay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.4. Agglutination Test
    • 4.4.1. Agglutination Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.5. Flow-through test/Immunoconcentration Assay
    • 4.5.1. Flow-through test/Immunoconcentration Assay Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.6. Molecular Diagnostics
    • 4.6.1. Molecular Diagnostics Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 4.7. Others
    • 4.7.1. Others Test Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 5. Point of Care Infectious Disease Testing Market: Disease Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Point of Care Infectious Disease Testing Market: Disease Movement Analysis, 2023 & 2030 (USD Billion)
  • 5.3. HIV POC
    • 5.3.1. HIV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.4. Clostridium Difficile POC
    • 5.4.1. Clostridium Difficile POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.5. HBV POC
    • 5.5.1. HBV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.6. Pneumonia or Streptococcus Associated Infections
    • 5.6.1. Pneumonia or Streptococcus Associated Infections Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.7. Respiratory Syncytial Virus (RSV) POC
    • 5.7.1. Respiratory Syncytial Virus (RSV) POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.8. HPV POC
    • 5.8.1. HPV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.9. Influenza/Flu POC
    • 5.9.1. Influenza/Flu POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.10. HCV POC
    • 5.10.1. HCV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.11. MRSA POC
    • 5.11.1. MRSA POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.12. TB and Drug-resistant TB POC
    • 5.12.1. TB and Drug-resistant TB POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.13. HSV POC
    • 5.13.1. HSV POC Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.14. COVID-19
    • 5.14.1. COVID-19 Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 5.15. Other Infectious Diseases
    • 5.15.1. Other Infectious Diseases Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 6. Point of Care Infectious Disease Testing Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Point of Care Infectious Disease Testing Market: End Use Movement Analysis, 2023 & 2030 (USD Billion)
  • 6.3. Clinics
    • 6.3.1. Clinics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.5. Home
    • 6.5.1. Home Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.6. Assisted Living Healthcare Facilities
    • 6.6.1. Assisted Living Healthcare Facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 6.7. Laboratory
    • 6.7.1. Laboratory Facilities Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 7. Point of Care Infectious Disease Testing Market: Regional Estimates & Trend Analysis

  • 7.1. Point of Care Infectious Disease Testing Market Share, By Region, 2023 & 2030 (USD Billion)
  • 7.2. North America
    • 7.2.1. North America Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.3. Europe
    • 7.3.1. Europe Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.2. U.K.
      • 7.3.2.1. U.K. Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.4. France
      • 7.3.4.1. France Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. China
      • 7.4.3.1. China Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. India
      • 7.4.4.1. India Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Point of Care Infectious Disease Diagnostic Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Latin America
    • 7.5.1. Latin America Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Point of Care Infectious Disease Testing Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Abbott
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. Thermo Fisher Scientific Inc
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. F. Hoffmann-La Roche Ltd
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. Siemens Healthineers
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Becton, Dickinson & Company
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Chembio Diagnostics Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. Trinity Biotech
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Cardinal Health
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Quest Diagnostics Incorporated
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Bio-Rad Laboratories Inc.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. bioMerieux SA
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives
    • 8.4.12. Sight Diagnostics Ltd.
      • 8.4.12.1. Participant's Overview
      • 8.4.12.2. Financial Performance
      • 8.4.12.3. Product Benchmarking
      • 8.4.12.4. Recent Developments/ Strategic Initiatives
    • 8.4.13. Gene POC
      • 8.4.13.1. Participant's Overview
      • 8.4.13.2. Financial Performance
      • 8.4.13.3. Product Benchmarking
      • 8.4.13.4. Recent Developments/ Strategic Initiatives
    • 8.4.14. Trivitron Healthcare
      • 8.4.14.1. Participant's Overview
      • 8.4.14.2. Financial Performance
      • 8.4.14.3. Product Benchmarking
      • 8.4.14.4. Recent Developments/ Strategic Initiatives
    • 8.4.15. OJ-Bio Ltd.
      • 8.4.15.1. Participant's Overview
      • 8.4.15.2. Financial Performance
      • 8.4.15.3. Product Benchmarking
      • 8.4.15.4. Recent Developments/ Strategic Initiatives
    • 8.4.16. Ortho-Clinical Diagnostics.
      • 8.4.16.1. Participant's Overview
      • 8.4.16.2. Financial Performance
      • 8.4.16.3. Product Benchmarking
      • 8.4.16.4. Recent Developments/ Strategic Initiatives